Rest-of-world markets offer good opportunities for rare disease companies to expand their sales potential beyond what U.S. & E.U. markets offer, and the requirements for market entry should be considered at a high level early on.
There is an urgent need for effective biomarkers to help classify COVID-19 patients based on risk, so that aggressive monitoring and appropriate therapy can be promptly directed to those more likely to get more severe illness.
As the COVID-19 pandemic continues to rage across the world, companies and national interests are racing to develop and secure access to SARS-CoV-2 vaccines and treatments. Over 180 vaccines are in various stages of development, with a handful having entered Phase 3 testing.